Just the other day, on Saturday, I ran down a pot stock "triple play" that offers investors a low-risk, easy-to-buy entry point into the fantastically lucrative world of weed investing.
These "pick-and-shovel" companies consist of some of my earliest, most prescient pot stock recommendations ever. Some of them are even included in the massive Roadmap to Marijuana Millions model portfolio my paid-up subscribers can access.
So it should come as no surprise that I hold these picks pretty close to the vest, watching them constantly.
One of the cornerstone picks there, a cannabis biotech that's returned high double- and triple-digit gains for folks following along, got some incredible news earlier this week.
It's a development so fresh it didn't make it into my roundup, so let me fill you in now…
About the Author
Michael A. Robinson is one of the top financial analysts working today. His book "Overdrawn: The Bailout of American Savings" was a prescient look at the anatomy of the nation's S&L crisis, long before the word "bailout" became part of our daily lexicon. He's a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style. His 30-year track record as a leading tech analyst has garnered him rave reviews, too. Today he is the editor of the monthly tech investing newsletter Nova-X Report as well as Radical Technology Profits, where he covers truly radical technologies – ones that have the power to sweep across the globe and change the very fabric of our lives – and profit opportunities they give rise to. He also explores "what's next" in the tech investing world at Strategic Tech Investor.